Innate Pharma (IPHA) Equity Average (2018 - 2025)

Innate Pharma (IPHA) has 7 years of Equity Average data on file, last reported at -$9.7 million in Q4 2025.

• For the quarter ending Q4 2025, Equity Average fell 148.06% year-over-year to -$9.7 million; the trailing twelve-month figure through Dec 2025 stood at -$9.7 million (down 148.06% YoY), and the FY2025 full-year result was -$7.9 million, down 124.24% from the prior year.
• Equity Average for Q4 2025 stood at -$9.7 million, down from $7.6 million in the prior quarter.
• Across five years, Equity Average topped out at $173.4 million in Q2 2021 and bottomed at -$9.7 million in Q4 2025.
• The 5-year median for Equity Average is $59.3 million (2023), against an average of $70.9 million.
• The widest annual swing landed in 2024, when Equity Average retreated 26.56%; it then sank 148.06% in 2025.
• A 5-year view of Equity Average shows it stood at $141.9 million in 2021, then slumped by 36.78% to $89.7 million in 2022, then slumped by 33.74% to $59.4 million in 2023, then slumped by 65.97% to $20.2 million in 2024, then tumbled by 148.06% to -$9.7 million in 2025.
• The last three Equity Average figures came in at -$9.7 million (Q4 2025), $7.6 million (Q2 2025), and $20.2 million (Q4 2024), per Business Quant data.

Peer Comparison